The new company, emerging from the NanoB2A group, will develop point-of-care diagnostic solutions based on nanophotonic biosensors for the rapid detection of life-threatening bacterial infections and antimicrobial resistance.
The new company, emerging from the NanoB2A group, will develop point-of-care diagnostic solutions based on nanophotonic biosensors for the rapid detection of life-threatening bacterial infections and antimicrobial resistance.